NCT00470470View on ClinicalTrials.gov

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

December 31, 2013

Study Completion Date

October 31, 2014

Conditions
Acral Lentiginous Malignant MelanomaRecurrent MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV Melanoma
Interventions
DRUG

imatinib mesylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (8)

10016

New York University Langone Medical Center, New York

10029

Mount Sinai Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

Weill Medical College of Cornell University, New York

33140

Mount Sinai Medical Center CCOP, Miami Beach

33401

Good Samaritan Medical Center, West Palm Beach

Palm Beach Cancer Institute-Main Office, West Palm Beach

90095

University of California at Los Angeles (UCLA ), Los Angeles

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00470470 - Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter